Mc Ilrath & Eck, LLC Cyclacel Pharmaceuticals, Inc. Transaction History

Mc Ilrath & Eck, LLC

  • $494 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023
BUY
$0.28 - $0.75 $700 - $1,875
2,500 Added 25.0%
12,500 $4,000
Q2 2023

Aug 07, 2023
SELL
$0.52 - $0.76 $8,497 - $12,419
-16,342 Reduced 62.04%
10,000 $5,000
Q3 2022

Oct 18, 2022
BUY
$1.23 - $21.9 $32,400 - $576,889
26,342 New
26,342 $38,000

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Mc Ilrath & Eck, LLC Portfolio

Follow Mc Ilrath & Eck, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Ilrath & Eck, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mc Ilrath & Eck, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email